Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies. Issue 11 (19th September 2022)

• Record Type: Journal Article
• Authors: Qualls, David; Kumar, Anita; Epstein-Peterson, Zachary D.
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 11(2022)
• Page Start: 2515
• Page End: 2527
• Publication Date: 2022-09-19
• Subjects: Mantle cell lymphoma -- immunotherapy -- microenvironment -- immunomodulators -- cellular therapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2086244
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Mantle cell lymphoma (MCL) is a morphologically and phenotypically heterogeneous subtype of non-Hodgkin lymphoma, and has historically been associated with poor outcomes. However, recent advances in our understanding of this disease have yielded new targeted and immune-based therapies with promising activity. Immune-based therapies such as monoclonal antibodies, immunomodulators, and CAR T cells have significantly improved outcomes and are now standard of care in MCL. In this review, we describe our current understanding of the immune microenvironment of MCL, discuss current immunotherapeutic approaches, and highlight promising novel immune-based therapies and combination therapies that may further improve outcomes for patients with MCL.